Article Text

Download PDFPDF
BENEFIT 8-year results provide further support for the long-term value of early treatment of multiple sclerosis

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Funding This work was supported by grants-in-aid for scientific research from the Ministry of Education, Culture, Sports, Science and Technology (22229008), and the Ministry of Health, Labour and Welfare of Japan.

  • Competing interests Dr Fujihara has received honoraria for speaking or consulting and research support from Bayer Schering Pharma, a manufacturer of interferon-β-1b.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles